

REMARKS

Claims 1-15 are pending for the Examiner's consideration. Applicants respectfully request favorable consideration of the pending claims.

Claims 1-15 were subject to a restriction requirement. Applicants hereby elect Group I, claims 1-5 and 13-15, with traverse. Applicants further elect the species Compound 1, and note that claims 1 and 5-15 read on the elected species. However, for the reasons set forth herein, Applicants believe the restriction requirement is improper and respectfully request that it be reconsidered and withdrawn.

The Examiner has indicated that the Group I and II claims are "related as product and process of use." However, none of the claims are directed to products, and all are directed to methods of use. Because there is no justification for a restriction requirement given, except the justification based on a factual error, the restriction requirement is improper and should be withdrawn.


The Examiner has also alleged that Group I and II claims are separately classified, but has not made the restriction requirement on that basis. Applicants note that claim 6 (Group II) simply corresponds to claim 1 (Group I), wherein "r" is zero, so a search of claim 1 will necessarily include a search of claim 6. Moreover, the elected species reads on both claims 1 and 6, so that if the elected species is found patentable, both Group I and Group II claims should be allowed, as all Group II claims depend directly or indirectly from claim 1.

Applicants believe all claims are now in condition for allowance. Should there be any issues that have not been addressed to the Examiners satisfaction, Applicants invite the Examiner to contact the undersigned attorney.

If any fees other than those submitted herewith are due in connection with this response, including the fee for any required extension of time (for which Applicants hereby petition), please charge such fees to Deposit Account No. 500329.

Respectfully submitted,

Date: August 8, 2006



Stephen D. Prodnuk
Attorney For Applicants
Registration No. 43,020

Agouron Pharmaceuticals, Inc.
A Pfizer Company
Legal Division – Intellectual Property
10777 Science Center Drive
San Diego, California 92121
Phone: (858) 622-3087
Fax: (858) 678-8233